Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 13/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22636149 | 1.00 | C3AR1 (0.37) | C3AR1ALDH1A1MAPTHPGDHDAC1 | |
| SCHEMBL25387512 | 0.80 | HDAC1 (0.40) | C3AR1ALDH1A1HDAC1HDAC8HDAC6 | |
| SCHEMBL5512580 | 0.77 | HDAC1 (0.41) | ALDH1A1HDAC1HDAC8HDAC6CES1 | |
| SCHEMBL12440555 | 0.76 | NPC1 (0.48) | ALDH1A1HPGD | |
| SCHEMBL12299144 | 0.75 | HDAC1 (0.36) | C3AR1HDAC1HDAC8HDAC6CES1 | |
| SCHEMBL16011737 | 0.74 | HDAC1 (0.40) | C3AR1ALDH1A1HDAC1HDAC8HDAC6 | |
| SCHEMBL22636117 | 0.72 | C3AR1 (0.62) | C3AR1ALDH1A1HPGDPOLB | |
| SCHEMBL22636119 | 0.72 | C3AR1 (0.62) | C3AR1ALDH1A1HPGDPOLB | |
| SCHEMBL10025442 | 0.71 | PTPN1 (0.36) | ALDH1A1HDAC1HDAC8HDAC6 | |
| SCHEMBL17365566 | 0.71 | ALDH1A1 (0.40) | C3AR1ALDH1A1HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| EP-4011904-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| WO-2020225095-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | C3AR1 261/4885ALDH1A1 2138/4885MAPT 4377/4885 |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | C3AR1 79/4885ALDH1A1 2231/4885MAPT 4465/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | C3AR1 261/4885ALDH1A1 2138/4885MAPT 4377/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | C3AR1 261/4885ALDH1A1 2138/4885MAPT 4377/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | C3AR1 261/4885ALDH1A1 2138/4885MAPT 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.